Americana Partners LLC Grows Stock Position in Johnson & Johnson $JNJ
Americana Partners LLC increased its stake in Johnson & Johnson (NYSE:JNJ) by 6.3% in the fourth quarter, bringing its total holdings to 197,070 shares valued at approximately $40.8 million. Wall Street analysts maintain a "Moderate Buy" rating for JNJ with an average target price of $253.04. Johnson & Johnson recently reported strong quarterly earnings, exceeding EPS and revenue estimates, and raised its quarterly dividend to $1.34 per share, offering a 2.3% yield.
Biogen Inc. (NASDAQ: BIIB) Navigates Alzheimer’s Drug Trajectory After Leqembi Updates
Biogen (NASDAQ: BIIB) is managing expectations for its Alzheimer’s drug Leqembi, which received full FDA approval but has seen slower-than-anticipated commercial uptake. Despite challenges in patient identification and reimbursement, Biogen anticipates accelerated adoption as infrastructure matures. The company is refocusing its pipeline on neuroscience and rare diseases, while analysts remain mixed on the stock's future, with upcoming quarterly earnings and Leqembi sales data being key catalysts.
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails
Shares of Denali Therapeutics (DNLI) fell 8% after its mid-stage study for Parkinson's disease, partnered with Biogen (BIIB), failed to meet its primary and secondary endpoints, leading to the discontinuation of BIIB122 for idiopathic Parkinson's disease. Despite this setback, Denali continues to advance other programs, including a phase IIa BEACON study for LRRK2 variants and recently secured FDA approval for Avlayah for Hunter Syndrome. The company also faces a terminated collaboration with Takeda for DNL593 but maintains a strong cash position to fund its pipeline.
Parkinson’s drug from Biogen, Denali comes up short
A Parkinson's disease drug developed by Biogen and Denali Therapeutics, BIIB122, failed its mid-stage clinical trial, showing no significant improvement in slowing disease progression. Consequently, Biogen and Denali will not pursue further development of the drug for "idiopathic" Parkinson's, although Denali plans to continue independent research for a subset of patients with a specific genetic variant. Analysts viewed the program as high-risk, so the news had minimal impact on Biogen's stock, which rose slightly, while Denali's shares fell by about 5%.
Crescent Biopharma (CBIO) FDA Approvals, PDUFA Dates & Drug Alerts 2026
Crescent Biopharma (CBIO) has not yet received any FDA approvals for its therapy CR-001, which is being investigated for the treatment of advanced solid tumors. The company recently announced a poster presentation for its ASCEND study of CR-001 at the 2026 ASCO Annual Meeting and previously reported dosing the first patient in its global Phase 1/2 clinical trial for the drug. Crescent Biopharma anticipates multiple data readouts for CR-001 starting in Q1 2027.
Elastic (NYSE:ESTC) Coverage Initiated by Analysts at William Blair
William Blair initiated coverage on Elastic (NYSE:ESTC) with an "outperform" rating, contributing to a generally positive outlook among Wall Street analysts despite some recent price target cuts. The consensus rating for Elastic is now a "Moderate Buy" with an average price target of $89.80. The company recently exceeded quarterly earnings expectations, reporting EPS of $0.73 against a $0.64 estimate, with revenue up 17.7% year over year.
Hewlett Packard Enterprise (NYSE:HPE) Hits New 12-Month High Following Analyst Upgrade
Hewlett Packard Enterprise (HPE) reached a new 52-week high after Morgan Stanley increased its price target from $25 to $33, maintaining an equal weight rating. Other analysts, including Bank of America and Citigroup, have also raised price targets and issued "buy" ratings, contributing to a "Moderate Buy" consensus. Despite recent insider share sales, HPE beat EPS expectations in its latest earnings report with an 18.4% revenue increase year-over-year and maintained its quarterly dividend.
Biogen Inc. (BIIB) Securities Fraud Investigation - Levi & Korsinsky
Levi & Korsinsky, LLP has announced a securities fraud investigation into Biogen Inc. (BIIB) after the company's shares dropped approximately 6.4% on May 14, 2026. This decline followed the disclosure that its Phase 2 CELIA trial for diranersen failed to meet its primary endpoint in treating early Alzheimer's disease. The investigation aims to determine if Biogen made misleading statements regarding its pipeline prospects and the CELIA trial's status.
Denali Therapeutics stock falls after Parkinson’s drug fails trial
Denali Therapeutics Inc. shares fell after its experimental Parkinson’s disease treatment, BIIB122 (DNL151), failed to meet primary or secondary endpoints in a late-stage clinical trial. Partner Biogen Inc. also saw a stock drop. Despite showing biological effects in reducing LRRK2 activity, the drug did not translate to clinical benefit in slowing disease progression.
Wedbush Cuts Price Target on Denali Therapeutics to $20 From $23, Keeps Outperform Rating
Wedbush has lowered its price target for Denali Therapeutics (DNLI) to $20 from $23, while maintaining an Outperform rating on the stock. This adjustment comes amidst other analyst revisions and recent news, including the discontinuation of a Parkinson's drug development program by Denali and Biogen. The article also provides a brief company profile of Denali Therapeutics, highlighting its focus on biotherapeutics for neurological diseases.
Lennox International, Inc. (NYSE:LII) Raises Dividend to $1.36 Per Share
Lennox International, Inc. (NYSE:LII) has announced a quarterly dividend increase to $1.36 per share, up from $1.30, marking its 16th consecutive year of dividend hikes. The construction company reported strong financial results, beating quarterly earnings and revenue expectations with $3.35 EPS and $1.14 billion in revenue. Despite a recent 2.6% trading dip, the company maintains a low payout ratio of 20.6% and projects solid FY2026 EPS guidance, indicating continued financial health and dividend coverage.
MGIC Investment Corporation (NYSE:MTG) Given Consensus Rating of "Hold" by Analysts
MGIC Investment Corporation (NYSE:MTG) has received an average "Hold" rating from analysts, with a consensus 1-year price target of $28.25. The company recently surpassed earnings expectations with an EPS of $0.76 but reported revenue below forecasts. MGIC announced a new $750 million share repurchase program and a quarterly dividend of $0.15 per share, indicating confidence in its valuation and commitment to shareholder returns.
Take-Two Interactive, Workday, Estee Lauder jump premarket; Deckers Outdoor slips
Several U.S. stocks, including Take-Two Interactive, Workday, and Estee Lauder, saw significant gains in premarket trading. Take-Two surged due to strong quarterly net bookings and the reaffirmation of the "Grand Theft Auto VI" launch date, while Workday and Zoom Communications also posted upbeat results. Deckers Outdoor, however, slipped despite increased sales, and Denali Therapeutics fell after its Parkinson's drug failed a mid-stage study.
Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish
Shares of Biogen (NASDAQ: BIIB) fell over 10% after its Alzheimer's drug, diranersen, missed its primary endpoint in the Phase 2 CELIA trial. Despite this, analysts remain bullish as the drug showed robust tau reductions and slowed cognitive decline, with the company advancing it to further development. Additionally, strong sales of Biogen's other Alzheimer's drug, Leqembi, and a planned acquisition of Apellis Pharmaceuticals provide a stable foundation for the company.
Wrapmanager Inc. Grows Stock Position in Netflix, Inc. $NFLX
Wrapmanager Inc. significantly increased its stake in Netflix, Inc. by 753.2% in the fourth quarter, now owning 13,532 shares valued at approximately $1.27 million. Other institutional investors also boosted their positions, with 80.93% of Netflix shares owned by hedge funds and institutions. The company has recently seen positive news regarding its ad-supported tier surpassing 250 million viewers and expansion into live programming, though some analysts express concerns about its valuation.
Biogen, Denali pull plug on Parkinson’s program after mid-stage flop
Biogen and Denali Therapeutics have discontinued their investigational Parkinson's disease drug, BIIB122 (DNL151), for idiopathic Parkinson's after it failed to meet primary and secondary endpoints in a Phase 2b study. The drug, an LRRK2 inhibitor, did not significantly slow disease progression. Despite this setback, Denali plans to continue a separate Phase 2a trial (BEACON) for LRRK2-associated Parkinson’s, a much smaller patient population.
Denali Therapeutics and Biogen discontinue BIIB122 after Phase 2b LUMA misses endpoints
Denali Therapeutics and Biogen have discontinued their Parkinson's disease drug BIIB122 after its Phase 2b LUMA study failed to meet primary and secondary endpoints in early-stage Parkinson’s disease. Despite showing high LRRK2 kinase inhibition, the drug did not slow disease progression compared to placebo. Denali will continue a separate Phase 2a BEACON study for LRRK2 variant carriers, with data expected in the first half of 2027.
Biogen, Denali discontinue Parkinson’s drug after trial fails
Biogen and Denali Therapeutics have announced the discontinuation of their Parkinson's drug, BIIB122, following the failure of its Phase 2b LUMA study to meet primary and secondary endpoints. The drug, an investigational small molecule inhibitor of LRRK2, did not slow disease progression in early-stage Parkinson’s patients. Despite this setback, Denali will continue a separate Phase 2a study for LRRK2 variant carriers, with results expected in early 2027, while Biogen also faces mixed results and analyst updates on other pipeline drugs.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
Pomerantz LLP is investigating potential securities fraud claims against Biogen Inc. on behalf of its investors. This investigation follows a 6.43% drop in Biogen's stock price on May 14, 2026, after the company announced "topline results" from its Phase 2 CELIA study, which missed its primary dose-response endpoint despite being described as "compelling." Investors who have suffered losses are encouraged to contact the law firm for more information.
[8-K] Denali Therapeutics Inc. Reports Material Event
Denali Therapeutics Inc. and Biogen announced that their Phase 2b LUMA study of BIIB122 (DNL151) for early-stage Parkinson’s disease failed to meet its primary and secondary endpoints. Consequently, development of BIIB122 for idiopathic Parkinson's disease will be discontinued. Denali will, however, continue with the separate Phase 2a BEACON study in individuals with Parkinson’s disease who carry a pathogenic LRRK2 variant, with data expected in the first half of 2027.
Biogen (BIIB) Halts Development of BIIB122 After Phase 2b Study Results
Biogen and Denali Therapeutics have announced the discontinuance of BIIB122's development for early-stage Parkinson's disease after its Phase 2b LUMA trial showed no significant impact on disease progression compared to a placebo. This setback comes despite Biogen's solid financial strength and profitability, as indicated by its GF Score™ of 76/100. The company's P/E ratio currently stands at 20.33, suggesting it may be fairly valued, though insider selling activity has been noted.
Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study
Biogen and Denali Therapeutics have decided to discontinue the development of their Parkinson's drug, BIIB122, after it failed to meet its primary goal in a mid-to-late stage study. The drug did not slow disease progression or show clinical benefit compared to a placebo, despite an acceptable safety profile. Denali plans to continue testing the drug in patients with a specific genetic mutation linked to Parkinson's disease.
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
Biogen and Denali Therapeutics announced that their Phase 2b LUMA study of BIIB122 (DNL151) for early-stage Parkinson’s disease did not meet its primary or secondary endpoints, leading to the discontinuation of BIIB122 development for idiopathic Parkinson's disease. Despite the negative results, the companies noted the drug was generally well-tolerated and showed kinase inhibition. Denali will continue its independent Phase 2a BEACON study in carriers of a pathogenic LRRK2 variant, with results anticipated in the first half of 2027.
Parkinson’s trial setback: Biogen, Denali halt BIIB122 program, await 2027 data
Biogen and Denali Therapeutics announced that their Phase 2b LUMA study for BIIB122 in early-stage Parkinson’s disease failed to meet its primary and secondary endpoints for slowing disease progression, leading to the discontinuation of the program for idiopathic Parkinson’s disease. Despite showing strong LRRK2 kinase inhibition by exploratory biomarkers, no clinical benefit was observed. Denali will continue a separate Phase 2a BEACON study for LRRK2 variant carriers, with data expected in the first half of 2027.
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
Biogen and Denali Therapeutics announced that their Phase 2b LUMA study for BIIB122 (DNL151) in early-stage Parkinson’s disease did not meet its primary or secondary endpoints. As a result, they will discontinue development of BIIB122 for idiopathic Parkinson’s disease. Denali will, however, continue an independent Phase 2a BEACON study for carriers of a pathogenic LRRK2 variant.
Revolution Medicines to host webcast on phase 3 trial results By Investing.com
Revolution Medicines (NASDAQ:RVMD) will host a webcast on May 31st to discuss positive results from its Phase 3 RASolute 302 clinical trial for daraxonrasib in metastatic pancreatic ductal adenocarcinoma. This data will be presented at the 2026 American Society of Clinical Oncology Annual Meeting. The company, which specializes in targeted therapies for RAS-addicted cancers, recently reported Q1 2026 earnings with a net loss but highlighted a strong cash position and strategic advancements despite increased operating expenses.
BIIB, DNLI Stocks Edge Lower After Hours: Parkinson’s Drug Misses Key Goals In Trial
Shares of Biogen (BIIB) and Denali Therapeutics (DNLI) fell after their experimental Parkinson's disease drug, BIIB122, failed to meet its primary and secondary goals in a mid-stage trial. The drug, designed to slow disease progression in early-stage idiopathic Parkinson’s, did not show improvement in motor and daily-living symptoms. While development for the broader idiopathic form will cease, Denali will continue testing BIIB122 in a smaller patient group with a specific genetic mutation.
Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study
Biogen and Denali Therapeutics have decided to stop developing their Parkinson's drug, BIIB122, after it failed to meet its primary goal in a mid-to-late stage study. The drug did not slow disease progression or improve symptoms compared to a placebo. Despite the setback, Denali plans to continue testing the drug in patients with a specific genetic mutation linked to Parkinson's disease.
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
Biogen and Denali Therapeutics announced that their Phase 2b LUMA study for BIIB122 (DNL151) in early-stage Parkinson’s disease did not meet its primary or secondary endpoints, leading to the discontinuation of BIIB122's development for idiopathic Parkinson's. Denali will continue a separate Phase 2a BEACON study for carriers of a pathogenic LRRK2 variant. The companies will share detailed findings at an upcoming scientific conference.
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?
Stoke Therapeutics (STOK) is advancing its lead candidate, zorevunersen, for Dravet syndrome, which has received Breakthrough Therapy designation from the FDA. The company's shares have significantly outperformed the industry, and it has a strategic collaboration with Biogen. With strong cash reserves and positive Zacks Rank, the article suggests Stoke Therapeutics is a good investment, also highlighting other top-ranked biotech stocks.
(BIIB) Movement as an Input in Quant Signal Sets
This article provides an AI-generated analysis for Biogen Inc. (BIIB), highlighting weak near-term sentiment despite long-term strength. It details specific trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report identifies a significant risk-reward short setup and offers real-time signals for institutional investors.
AstraZeneca PLC stock (US6549022043): analysts update views as pipeline news keeps investors alert
AstraZeneca PLC (US6549022043) remains a focus for investors in May 2026 due to updated analyst commentary and new pipeline developments, particularly in its respiratory portfolio. Analysts see a moderate upside potential for the stock, with an average 12-month price target of USD 205.33, implying differing views on the company's future growth trajectory. The company’s pipeline success, especially in biologics for respiratory conditions, along with its strong presence in oncology and cardiovascular treatments, are key drivers for its valuation and long-term earnings profile.
Inmune Bio Inc stock (US45764T1060): eyes on upcoming 2025 results and Alzheimer’s pipeline
Inmune Bio Inc (INMB) is preparing to release its full-year 2025 financial results and provide a corporate update on March 30, 2026. The clinical-stage biotechnology company focuses on developing therapies for neuroinflammatory and oncological diseases, with a significant pipeline in Alzheimer's disease. Investors are closely watching for updates on cash runway, strategic priorities, and clinical milestones, given the company's reliance on capital markets and the early stage of its drug development.
Biogen stock (US09062X1037): FDA decision keeps investors focused
Biogen's stock remains a key focus for investors, driven by its Alzheimer’s treatment Leqembi and strong neurology portfolio. Recent U.S. regulatory progress for Leqembi has reinforced its strategic importance, highlighting the company's dependence on specialist neurology uptake and commercialization efforts. Investors track Biogen for its potential in health care innovation and its sensitivity to regulatory milestones, making it a headline-driven biotechnology stock.
Biogen Inc. stock underperforms Wednesday when compared to competitors
Shares of Biogen Inc. (BIIB) fell 1.45% to $187.80 on Wednesday, marking its third consecutive day of losses. This occurred despite a generally favorable trading session for the broader market, with the S&P 500 Index and Dow Jones Industrial Average both seeing gains.
Apellis Shares Disappear After Biogen’s $5.6 Billion Buy—One Play Left
Apellis Pharmaceuticals shares have been delisted from Nasdaq following Biogen's $5.6 billion acquisition. Investors received $41 per share in cash, plus a Contingent Value Right (CVR) tied to future sales of Apellis's drugs, Syfovre and Empaveli. The focus now shifts to Biogen's ability to generate significant revenue from these drugs to justify the acquisition, with the CVR offering potential additional payouts if sales milestones are met.
How Biogen’s Diranersen Alzheimer’s Bet Will Impact Biogen (BIIB) Investors
Biogen has announced its decision to advance diranersen, a tau-targeting antisense therapy for early Alzheimer's disease, into registrational development despite missing the primary dose-response endpoint in its Phase 2 CELIA trial. This move signifies a broadening approach in Alzheimer's R&D beyond amyloid, potentially creating a second pillar for Biogen's Alzheimer's franchise alongside LEQEMBI. While diranersen offers a longer-term catalyst and diversification, investors should consider ongoing commercial and pricing pressures on existing therapies.
Ionis Rises As Diranersen Phase 2 Spurs Biogen Registrational Plans
Ionis Pharmaceuticals saw its stock rise after Biogen announced plans for registrational studies for diranersen, following positive Phase 2 CELIA data in early Alzheimer's disease. The antisense therapy, which targets tau, showed robust biomarker and cognitive improvements, positioning Ionis for potential late-stage development in a large disease area. Despite a primary endpoint miss on dose response, the overall data package was deemed strong enough to pursue further investment.
Incyte (INCY) 10K Form and Latest SEC Filings 2026
This article provides a comprehensive overview of Incyte (INCY) SEC filings, highlighting that the company has submitted over 687 documents since 2017. It details recent filings such as a Form 4/A on May 20, 2026, and an 8-K current report on April 28, 2026, alongside a 10-Q quarterly report on the same date. The page also explains the significance of different SEC filing types (10-K, 10-Q, 8-K, Form 4) for investors, emphasizing their role in providing verified financial data and insights into corporate events and insider trading.
Are Wall Street Analysts Bullish on Biogen Stock?
Barchart.com reports that Biogen Inc. (BIIB) stock has outperformed the broader market and its industry benchmark over the past year, with a significant rally driven by better-than-expected Q1 2026 earnings. Wall Street analysts have a "Moderate Buy" consensus rating for BIIB, with a growing bullish sentiment and a mean price target indicating a substantial premium from current market prices.
Is It Time To Reconsider Vertex Pharmaceuticals (VRTX) After The Recent Share Price Pullback
Vertex Pharmaceuticals (VRTX) has experienced a recent share price pullback, leading to questions about its current valuation. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 46.1%, with an estimated intrinsic value of $805.27 per share against a current price of $434.31. However, its P/E ratio is above the biotech industry average, hinting that the current valuation is "about right" when considering its growth profile and risks.
Immunic names Michael Bonney as board chair By Investing.com
Immunic, Inc. has appointed Michael W. Bonney as Chair of its Board of Directors, effective May 16. Bonney brings over 30 years of biopharmaceutical industry experience, including significant roles at Biogen Inc., Cubist Pharmaceuticals, and Zeneca Pharmaceuticals. His appointment comes at a crucial time for Immunic, as the company anticipates phase 3 ENSURE trial readouts for vidofludimus calcium in relapsing MS.
BIIB Investor Alert: Levi & Korsinsky Investigates Biogen Inc. (BIIB) for Potential Securities Fraud
Levi & Korsinsky is investigating Biogen Inc. (BIIB) for potential securities fraud after the company's stock fell 6.4% on May 14, 2026. This drop occurred following the disclosure that its Phase 2 CELIA trial for Alzheimer's candidate diranersen failed to meet its primary endpoint. Shareholders who experienced losses are encouraged to contact Levi & Korsinsky for a free evaluation of potential claims.
Zorevunersen tied to long-term benefits in Dravet syndrome
Four-year data from long-term extension studies (SWALLOWTAIL and LONGWING) for Stoke Therapeutics' zorevunersen show sustained seizure reductions and cognitive and behavioral improvements in patients with Dravet syndrome. The investigational therapy, designed to increase functional NaV1.1 production, was generally well tolerated. Enrollment for the global Phase 3 EMPEROR trial is expected to complete in June, with data anticipated in mid-2027 to support a U.S. regulatory submission.
Immunic Appoints Michael Bonney as Board Chair
Immunic (IMUX) has appointed Michael W. Bonney as Chair of its Board of Directors, effective May 16, 2026. Bonney, a veteran biopharmaceutical executive, brings over 30 years of experience, including significant roles in Biogen and Cubist Pharmaceuticals, aiming to strengthen Immunic's governance and commercial expertise as it advances its lead MS therapy through Phase 3 trials. The appointment supports Immunic's transition from a development-stage biotech to a fully integrated commercial-stage company.
Press Release: Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
Immunic, Inc. has announced the appointment of Michael W. Bonney as the new Chair of its Board of Directors. Bonney brings extensive experience from his roles at MedImmune and Cubist Pharmaceuticals, and currently serves on the boards of Alexion Pharmaceuticals and Magenta Therapeutics. His appointment is expected to provide strategic leadership as Immunic advances its clinical programs.
Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
Immunic, Inc. has announced the appointment of Michael W. Bonney as the Chair of its Board of Directors, effective May 16, 2026. Bonney brings over 30 years of biopharmaceutical leadership experience, including pivotal roles in the commercialization of Avonex® for Multiple Sclerosis during his time at Biogen and serving as CEO of Cubist Pharmaceuticals. His appointment comes at a critical time for Immunic as it advances its lead development program, vidofludimus calcium, through phase 3 clinical trials for relapsing MS.
Biotech veteran Michael Bonney becomes Immunic (NASDAQ: IMUX) chair
Immunic, Inc. has appointed veteran biopharmaceutical executive Michael W. Bonney as Chair of its Board of Directors, effective May 16, 2026. Bonney brings over three decades of leadership experience, including his role as CEO of Cubist Pharmaceuticals and significant contributions to the launch of Avonex for multiple sclerosis. His appointment coincides with an increase in the board size and an option grant, as Immunic advances its lead program, vidofludimus calcium, through phase 3 trials.
Ranch seasoning sold at Walmart recalled because of Salmonella
Blackstone Products has recalled its Parmesan Ranch seasoning sold at Walmart and on its website due to potential Salmonella contamination. The recall stems from a supplier's dry milk powder being contaminated, and three specific lots of the seasoning are affected. No illnesses have been reported, but consumers are advised to seek medical attention if they experience Salmonella symptoms after consuming the product.
Takeda cuts send layoffs soaring in May, rising year over year
BioPharma layoffs are significantly increasing in May 2026, primarily driven by Takeda's announcement of 4,500 job cuts. While fewer companies are reporting layoffs compared to the previous year, the number of affected employees is rising, with a 24% increase in total layoffs from January 1 to May 15, 2026, compared to the same period in 2025. This trend indicates deeper cuts from fewer companies, with other major layoffs announced by BioNTech and Viatris also contributing to the surge.
